Shopping Cart 0
Cart Subtotal
USD 0

Critical Limb Ischemia - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Critical Limb Ischemia-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Critical Limb Ischemia-Pipeline Review, H2 2018, provides an overview of the Critical Limb Ischemia (Cardiovascular) pipeline landscape.

Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease (PAD). It is caused by chronic inflammatory processes associated with atherosclerosis that result in reduced blood flow to the legs, feet and hands. Symptoms include pain or numbness in feet or toes, sores, skin infections will not heal. Treatment goals for CLI include reducing the number of cardiovascular risk factors (such as quitting smoking and reduction of cholesterol), relieving pain, healing ulcers, preventing major amputation, improving quality of life and increasing survival.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Critical Limb Ischemia-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Critical Limb Ischemia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Critical Limb Ischemia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Critical Limb Ischemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 2, 18, 2, 1 and 10 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Critical Limb Ischemia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Critical Limb Ischemia (Cardiovascular).

- The pipeline guide reviews pipeline therapeutics for Critical Limb Ischemia (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Critical Limb Ischemia (Cardiovascular) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Critical Limb Ischemia (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Critical Limb Ischemia (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Critical Limb Ischemia (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Critical Limb Ischemia (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 5

Critical Limb Ischemia-Overview 6

Critical Limb Ischemia-Therapeutics Development 7

Critical Limb Ischemia-Therapeutics Assessment 16

Critical Limb Ischemia-Companies Involved in Therapeutics Development 24

Critical Limb Ischemia-Drug Profiles 35

Critical Limb Ischemia-Dormant Projects 124

Critical Limb Ischemia-Discontinued Products 126

Critical Limb Ischemia-Product Development Milestones 127

Appendix 137


List Of Figure

List of Figures

Number of Products under Development for Critical Limb Ischemia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Critical Limb Ischemia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Critical Limb Ischemia-Pipeline by AnGes Inc, H2 2018

Critical Limb Ischemia-Pipeline by apceth Biopharma GmbH, H2 2018

Critical Limb Ischemia-Pipeline by Athersys Inc, H2 2018

Critical Limb Ischemia-Pipeline by BiogenCell Ltd, H2 2018

Critical Limb Ischemia-Pipeline by Caladrius Biosciences Inc, H2 2018

Critical Limb Ischemia-Pipeline by Cynata Therapeutics Ltd, H2 2018

Critical Limb Ischemia-Pipeline by Hemostemix Inc, H2 2018

Critical Limb Ischemia-Pipeline by Histocell SL, H2 2018

Critical Limb Ischemia-Pipeline by ID Pharma Co Ltd, H2 2018

Critical Limb Ischemia-Pipeline by Integene International Holdings LLC, H2 2018

Critical Limb Ischemia-Pipeline by Juventas Therapeutics Inc, H2 2018

Critical Limb Ischemia-Pipeline by Kang Stem Biotech Co Ltd, H2 2018

Critical Limb Ischemia-Pipeline by Kasiak Research Pvt Ltd, H2 2018

Critical Limb Ischemia-Pipeline by Neurofx Inc, H2 2018

Critical Limb Ischemia-Pipeline by Nissan Chemical Industries Ltd, H2 2018

Critical Limb Ischemia-Pipeline by Pharmicell Co Ltd, H2 2018

Critical Limb Ischemia-Pipeline by Pluristem Therapeutics Inc, H2 2018

Critical Limb Ischemia-Pipeline by ReNeuron Group Plc, H2 2018

Critical Limb Ischemia-Pipeline by Reven Pharmaceuticals Inc, H2 2018

Critical Limb Ischemia-Pipeline by Rexgenero Ltd, H2 2018

Critical Limb Ischemia-Pipeline by Symic Biomedical Inc, H2 2018

Critical Limb Ischemia-Pipeline by TaiGen Biotechnology Co Ltd, H2 2018

Critical Limb Ischemia-Pipeline by U.S. Stem Cell Inc, H2 2018

Critical Limb Ischemia-Pipeline by VESSL Therapeutics Ltd, H2 2018

Critical Limb Ischemia-Pipeline by ViroMed Co Ltd, H2 2018

Critical Limb Ischemia-Pipeline by YiChang Humanwell Pharmaceutical Co Ltd, H2 2018

Critical Limb Ischemia-Dormant Projects, H2 2018

Critical Limb Ischemia-Dormant Projects, H2 2018 (Contd..1), H2 2018

Critical Limb Ischemia-Discontinued Products, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Critical Limb Ischemia Therapeutic Products under Development, Key Players in Critical Limb Ischemia Therapeutics, Critical Limb Ischemia Pipeline Overview, Critical Limb Ischemia Pipeline, Critical Limb Ischemia Pipeline Assessment


Companies

AnGes Inc

apceth Biopharma GmbH

Athersys Inc

BiogenCell Ltd

Caladrius Biosciences Inc

Cynata Therapeutics Ltd

Hemostemix Inc

Histocell SL

ID Pharma Co Ltd

Integene International Holdings LLC

Juventas Therapeutics Inc

Kang Stem Biotech Co Ltd

Kasiak Research Pvt Ltd

Neurofx Inc

Nissan Chemical Industries Ltd

Pharmicell Co Ltd

Pluristem Therapeutics Inc

ReNeuron Group Plc

Reven Pharmaceuticals Inc

Rexgenero Ltd

Symic Biomedical Inc

TaiGen Biotechnology Co Ltd

U.S. Stem Cell Inc

VESSL Therapeutics Ltd

ViroMed Co Ltd

YiChang Humanwell Pharmaceutical Co Ltd